NeoGenomics (NASDAQ: NEO) reported Q2 EPS of ($0.04), $0.06 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $87 million versus the consensus estimate of $86.55 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.